PRESS RELEASES Brian DeBeer 10/13/26 Brian DeBeer 10/13/26 Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement Read More Brian DeBeer 9/21/26 Brian DeBeer 9/21/26 Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement Read More Alona Tal 9/8/26 Alona Tal 9/8/26 Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business Read More Alona Tal 8/24/26 Alona Tal 8/24/26 Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum Read More Alona Tal 8/11/26 Alona Tal 8/11/26 Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration Read More Alona Tal 6/10/26 Alona Tal 6/10/26 Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives Read More Alona Tal 5/20/26 Alona Tal 5/20/26 Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility Read More Alona Tal 5/15/26 Alona Tal 5/15/26 Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe Read More Alona Tal 4/24/26 Alona Tal 4/24/26 Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing Read More Alona Tal 4/6/26 Alona Tal 4/6/26 Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities Read More Amir Reichman 4/1/26 Amir Reichman 4/1/26 Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration Read More Alona Tal 3/19/26 Alona Tal 3/19/26 Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026 Read More Alona Tal 3/2/26 Alona Tal 3/2/26 Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept Read More Alona Tal 2/25/26 Alona Tal 2/25/26 Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform Read More Alona Tal 2/17/26 Alona Tal 2/17/26 Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm Read More Alona Tal 1/7/26 Alona Tal 1/7/26 Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL Read More Alona Tal 12/2/25 Alona Tal 12/2/25 Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances Read More Alona Tal 10/6/25 Alona Tal 10/6/25 Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities Read More Alona Tal 9/2/25 Alona Tal 9/2/25 Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet Read More Alona Tal 7/29/25 Alona Tal 7/29/25 Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN Read More Older Posts
Brian DeBeer 10/13/26 Brian DeBeer 10/13/26 Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement Read More
Brian DeBeer 9/21/26 Brian DeBeer 9/21/26 Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement Read More
Alona Tal 9/8/26 Alona Tal 9/8/26 Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business Read More
Alona Tal 8/24/26 Alona Tal 8/24/26 Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum Read More
Alona Tal 8/11/26 Alona Tal 8/11/26 Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration Read More
Alona Tal 6/10/26 Alona Tal 6/10/26 Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives Read More
Alona Tal 5/20/26 Alona Tal 5/20/26 Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility Read More
Alona Tal 5/15/26 Alona Tal 5/15/26 Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe Read More
Alona Tal 4/24/26 Alona Tal 4/24/26 Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing Read More
Alona Tal 4/6/26 Alona Tal 4/6/26 Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities Read More
Amir Reichman 4/1/26 Amir Reichman 4/1/26 Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration Read More
Alona Tal 3/19/26 Alona Tal 3/19/26 Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026 Read More
Alona Tal 3/2/26 Alona Tal 3/2/26 Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept Read More
Alona Tal 2/25/26 Alona Tal 2/25/26 Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform Read More
Alona Tal 2/17/26 Alona Tal 2/17/26 Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm Read More
Alona Tal 1/7/26 Alona Tal 1/7/26 Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL Read More
Alona Tal 12/2/25 Alona Tal 12/2/25 Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances Read More
Alona Tal 10/6/25 Alona Tal 10/6/25 Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities Read More
Alona Tal 9/2/25 Alona Tal 9/2/25 Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet Read More
Alona Tal 7/29/25 Alona Tal 7/29/25 Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN Read More
